glp-1 ourlyard Support, 60 Vegan Capsules Ourlyard® 𝑺𝒊𝒙-𝒊𝒏-𝑶𝒏𝒆 𝑯𝒆𝒂𝒍𝒕𝒉 𝑺𝒐𝒍𝒖𝒕𝒊𝒐𝒏 𝑶𝒓𝒂𝒍

2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated

It can take time for the mind to catch up with changes in the body

These insights have driven the development of synthetic GLP-1R/GCGR co-agonists aimed at achieving long-term metabolic benefits

& Hayes, M

At the same time, we observed a steep decrease in first-time off-label prescribing of Mounjaro